A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (I-FIRST)
NCT 05182931 Brief Summary This prospective, multi-centre, open label, non-randomised phase II…
Read more arrow_forwardNCT 05182931 Brief Summary This prospective, multi-centre, open label, non-randomised phase II…
Read more arrow_forwardNCT 06815575 Brief Summary This is a multi-centre, two-part, open-label, phase 1,…
Read more arrow_forwardNCT 05332574 Brief Summary This is a Phase 1/2 study of GB263T…
Read more arrow_forwardNCT 05981703 Brief Summary This is an open-label, multicenter, and nonrandomized dose…
Read more arrow_forwardNCT 05094336 Brief Summary The primary objective of Parts 1 and 2…
Read more arrow_forwardNCT 06669975 Brief Summary This is a Phase 1/2, multi-regional, multi-center, open-label,…
Read more arrow_forwardNCT 06130553 Brief Summary This is a first time in human (FTiH)…
Read more arrow_forwardNCT 05381909 Brief Summary This study aims to understand how safe and…
Read more arrow_forwardNCT 05935098 Brief Summary This study aims to test the safety, tolerability,…
Read more arrow_forwardNCT 06803680 Brief Summary The goal of this clinical trial is to…
Read more arrow_forward